Expand ALNY Menu
ALNY MENU

ALNY Latest Press Releases

-- December 12, 2025 --

Annual Changes to the Nasdaq-100 Index Globe Newswire 8:00 PM

-- December 11, 2025 --

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027 Business Wire 7:00 AM

-- December 3, 2025 --

Alnylam Pharmaceuticals Announces Changes to Board of Directors Business Wire 8:00 AM

-- November 8, 2025 --

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM Business Wire 4:57 PM

-- November 4, 2025 --

Alnylam to Webcast Presentations at Upcoming November Investor Conferences Business Wire 8:00 AM

-- October 30, 2025 --

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress Business Wire 8:00 AM

-- October 16, 2025 --

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results Business Wire 8:00 AM

-- October 13, 2025 --

Cardiovascular Drugs Market Size to Reach US$ 247.8 Billion by 2033, Driven by Rising Cardiovascular Disease Cases and Lifestyle Changes | According to DataM Intelligence PRNewswire 11:00 AM

-- October 1, 2025 --

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran Business Wire 7:30 AM

-- September 28, 2025 --

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Business Wire 11:13 AM

-- September 18, 2025 --

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine PRNewswire 9:15 AM

-- September 9, 2025 --

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes Business Wire 11:16 PM

-- September 8, 2025 --

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes Business Wire 4:15 PM

-- September 1, 2025 --

Positive Outlook for Alnylam Pharma Amid Promising Cardiovascular Drug Developments and Strategic Partnerships TipRanks 11:09 AM
Alnylam reports new data from HELIOS-B Phase 3 study TipRanks 8:39 AM

-- August 31, 2025 --

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM Business Wire 5:15 AM

-- August 30, 2025 --

Roche, Alnylam to initiate Phase 3 cardiovascular outcomes trial of zilebesiran TipRanks 5:07 PM
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension Globe Newswire 10:30 AM
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension Business Wire 10:30 AM
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial Business Wire 10:30 AM

-- August 26, 2025 --

Scenic Enters License and Research Agreement with Alnylam Globe Newswire 5:00 AM

-- August 11, 2025 --

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025 Business Wire 8:00 AM

-- July 31, 2025 --

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress Business Wire 8:00 AM

-- July 17, 2025 --

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results Business Wire 8:00 AM
Market Data Delayed 15 Minutes